Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18817224 | 1.00 | TOP2A (0.35) | TOP2A | |
| SCHEMBL16777798 | 1.00 | TOP2A (0.35) | TOP2A | |
| SCHEMBL13526167 | 0.86 | TOP2A (0.37) | TOP2A | |
| SCHEMBL30262360 | 0.86 | TOP2A (0.37) | TOP2A | |
| SCHEMBL16777627 | 0.86 | TOP2A (0.37) | TOP2A | |
| SCHEMBL14028075 | 0.86 | TOP2A (0.37) | TOP2A | |
| SCHEMBL19464443 | 0.86 | TOP2A (0.37) | TOP2A | |
| SCHEMBL13696835 | 0.86 | TOP2A (0.37) | TOP2A | |
| SCHEMBL13916937 | 0.86 | TOP2A (0.37) | TOP2A | |
| SCHEMBL20805194 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037078-A1 | 2' -DISUBSTITUTED NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER | COCRYSTAL PHARMA, INC. (US) | 2017-02-09 | — | — | US | disclosed |
| WO-2015164812-A1 | 2' -DISUBSTITUTED NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER | COCRYSTAL PHARMA, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037078-A1 | 2' -DISUBSTITUTED NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER | HAVCR2, HCCS, NAMPT | TOP2A 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.